<!DOCTYPE html>
<html lang="de">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Aminos√§urest√∂rungen - Teil 1</title>
<style>
@import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');

* {
margin: 0;
padding: 0;
box-sizing: border-box;
}

:root {
--primary-color: #667eea;
--secondary-color: #764ba2;
--accent-color: #f093fb;
--success-color: #4facfe;
--warning-color: #fa709a;
--danger-color: #ff6b6b;
--info-color: #74b9ff;
--text-primary: #2d3748;
--text-secondary: #4a5568;
--text-muted: #718096;
--bg-white: #ffffff;
--bg-light: #f8fafc;
--bg-lighter: #f1f5f9;
--border-radius: 16px;
--border-radius-lg: 24px;
--spacing-xs: 8px;
--spacing-sm: 16px;
--spacing-md: 24px;
--spacing-lg: 32px;
--spacing-xl: 48px;
--shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
--shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
--shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
}

body {
font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
line-height: 1.6;
color: var(--text-primary);
background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
min-height: 100vh;
}

.container {
max-width: 1400px;
margin: 0 auto;
padding: var(--spacing-md);
}

/* Header */
.header {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
}

.header h1 {
background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
background-size: 200% 200%;
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: clamp(2rem, 5vw, 3.5rem);
font-weight: 700;
margin-bottom: var(--spacing-sm);
animation: gradientShift 4s ease-in-out infinite;
}

@keyframes gradientShift {
0%, 100% { background-position: 0% 50%; }
50% { background-position: 100% 50%; }
}

.header p {
color: var(--text-secondary);
font-size: 1.3rem;
font-weight: 400;
}

/* Progress bar */
.progress-container {
background: var(--bg-lighter);
border-radius: 50px;
height: 10px;
margin-top: var(--spacing-md);
overflow: hidden;
}

.progress-fill {
background: linear-gradient(90deg, var(--success-color), #00f2fe);
height: 100%;
border-radius: 50px;
transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
position: relative;
overflow: hidden;
}

.progress-fill::after {
content: '';
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
animation: progressShimmer 2s infinite;
}

@keyframes progressShimmer {
0% { transform: translateX(-100%); }
100% { transform: translateX(100%); }
}

/* Navigation */
.navigation {
background: var(--bg-white);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
display: flex;
flex-wrap: wrap;
gap: var(--spacing-sm);
justify-content: center;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.nav-btn {
background: var(--bg-light);
border: 2px solid #e2e8f0;
color: var(--text-primary);
padding: 16px 24px;
border-radius: 50px;
cursor: pointer;
font-size: 14px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
text-transform: uppercase;
letter-spacing: 0.5px;
}

.nav-btn:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
border-color: var(--primary-color);
}

.nav-btn.active {
background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
color: white;
border-color: var(--primary-color);
box-shadow: var(--shadow-md);
}

/* Content sections */
.content-section {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
display: none;
}

.content-section.active {
display: block;
animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

@keyframes slideInUp {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.section-title {
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: 2.5rem;
font-weight: 700;
margin-bottom: var(--spacing-lg);
position: relative;
padding-bottom: var(--spacing-sm);
}

.section-title::after {
content: '';
position: absolute;
bottom: 0;
left: 0;
width: 60px;
height: 4px;
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
border-radius: 2px;
animation: expandWidth 0.8s ease-out 0.3s both;
}

@keyframes expandWidth {
from { width: 0; }
to { width: 60px; }
}

/* Subsections */
.subsection {
margin-bottom: var(--spacing-lg);
padding: var(--spacing-lg);
background: var(--bg-light);
border-radius: var(--border-radius);
border: 1px solid #e2e8f0;
transition: all 0.3s ease;
}

.subsection:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
}

.subsection h3 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.5rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.subsection h3::before {
content: '';
width: 4px;
height: 24px;
background: linear-gradient(135deg, var(--success-color), #00f2fe);
border-radius: 2px;
}

.subsection p {
color: var(--text-secondary);
margin-bottom: 1rem;
line-height: 1.7;
}

.subsection ul {
color: var(--text-secondary);
padding-left: 1.5rem;
}

.subsection li {
margin-bottom: 0.5rem;
}

/* Tables */
.clinical-table {
width: 100%;
border-collapse: separate;
border-spacing: 0;
margin: var(--spacing-md) 0;
background: var(--bg-white);
border-radius: var(--border-radius);
overflow: hidden;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.clinical-table th {
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
color: white;
padding: var(--spacing-md);
text-align: left;
font-weight: 600;
font-size: 0.95rem;
text-transform: uppercase;
letter-spacing: 0.5px;
}

.clinical-table td {
padding: var(--spacing-md);
border-bottom: 1px solid #f1f5f9;
transition: all 0.3s ease;
color: var(--text-primary);
}

.clinical-table tbody tr:hover {
background: #f8fafc;
}

.clinical-table tbody tr:last-child td {
border-bottom: none;
}

/* Pathway diagrams */
.pathway-diagram {
background: var(--bg-white);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.pathway-diagram h4 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
text-align: center;
}

.pathway-diagram h5 {
color: var(--text-primary);
margin-bottom: var(--spacing-sm);
font-weight: 600;
}

.pathway-diagram p {
color: var(--text-secondary);
}

/* Enzyme boxes */
.enzyme-box {
display: inline-block;
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
color: white;
padding: 12px 20px;
margin: 6px;
border-radius: 12px;
font-weight: 600;
transition: all 0.3s ease;
box-shadow: var(--shadow-sm);
}

.enzyme-box:hover {
transform: translateY(-2px) scale(1.05);
box-shadow: var(--shadow-md);
}

.enzyme-box.defect {
background: linear-gradient(135deg, var(--danger-color), #ee5a24);
animation: pulseGlow 2s infinite;
}

@keyframes pulseGlow {
0%, 100% {
transform: scale(1);
box-shadow: var(--shadow-sm);
}
50% {
transform: scale(1.02);
box-shadow: var(--shadow-md);
}
}

.arrow {
display: inline-block;
margin: 0 var(--spacing-sm);
font-size: 1.8rem;
color: var(--primary-color);
transition: all 0.3s ease;
}

.arrow:hover {
transform: scale(1.2);
color: var(--accent-color);
}

/* Highlight boxes */
.highlight-box {
background: linear-gradient(135deg, #fff7ed, #fed7aa);
border: 2px solid var(--warning-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
position: relative;
box-shadow: var(--shadow-sm);
}

.highlight-box::before {
content: '‚ö†Ô∏è';
position: absolute;
top: -12px;
left: 24px;
background: linear-gradient(135deg, var(--warning-color), #fee140);
padding: 8px 12px;
border-radius: 50%;
font-size: 1.2rem;
box-shadow: var(--shadow-sm);
}

.highlight-box h4 {
color: #92400e;
margin-bottom: var(--spacing-sm);
margin-top: var(--spacing-sm);
font-weight: 600;
}

.highlight-box p, .highlight-box ul, .highlight-box li {
color: #92400e;
}

/* Case study boxes */
.case-study {
background: linear-gradient(135deg, #f0fdf4, #dcfce7);
border: 2px solid var(--success-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.case-study h4 {
color: #166534;
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.case-study p, .case-study ul, .case-study li {
color: #166534;
}

/* Metabolite boxes */
.metabolite-box {
display: inline-block;
background: linear-gradient(135deg, var(--warning-color), #fee140);
color: white;
padding: 10px 16px;
margin: 4px;
border-radius: 8px;
font-size: 0.9rem;
font-weight: 500;
transition: all 0.3s ease;
box-shadow: var(--shadow-sm);
}

.metabolite-box:hover {
transform: translateY(-2px) scale(1.05);
box-shadow: var(--shadow-md);
}

/* Buttons */
.next-step {
text-align: center;
margin-top: var(--spacing-xl);
}

.next-btn {
background: linear-gradient(135deg, var(--success-color), #00f2fe);
color: white;
border: none;
padding: 18px 36px;
border-radius: 50px;
cursor: pointer;
font-size: 16px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
box-shadow: var(--shadow-md);
text-transform: uppercase;
letter-spacing: 1px;
}

.next-btn:hover {
transform: translateY(-4px) scale(1.05);
box-shadow: var(--shadow-lg);
}

.part-info {
background: linear-gradient(135deg, #eff6ff, #dbeafe);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-sm);
}

.part-info h3 {
color: var(--info-color);
margin-bottom: var(--spacing-sm);
}

.part-info p {
color: var(--text-secondary);
}

/* Responsive design */
@media (max-width: 768px) {
.container {
padding: var(--spacing-sm);
}

.header h1 {
font-size: 2.5rem;
}

.header p {
font-size: 1.1rem;
}

.navigation {
flex-direction: column;
}

.nav-btn {
width: 100%;
text-align: center;
}

.content-section {
padding: var(--spacing-md);
}

.section-title {
font-size: 2rem;
}

.subsection {
padding: var(--spacing-md);
}
}

@media (max-width: 480px) {
.header {
padding: var(--spacing-md);
}

.header h1 {
font-size: 2rem;
}

.section-title {
font-size: 1.8rem;
}
}

/* Animation stagger */
.subsection {
animation: fadeInStagger 0.6s ease-out both;
}

@keyframes fadeInStagger {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.subsection:nth-child(1) { animation-delay: 0.1s; }
.subsection:nth-child(2) { animation-delay: 0.2s; }
.subsection:nth-child(3) { animation-delay: 0.3s; }
.subsection:nth-child(4) { animation-delay: 0.4s; }
.subsection:nth-child(5) { animation-delay: 0.5s; }
</style>
</head>

<body>
<div class="container">
<div class="header">
<h1>üß¨ Aminos√§urest√∂rungen</h1>
<p>Teil 1: Grundlagen & Diagnostik</p>
<div class="progress-container">
<div class="progress-fill" id="progressBar" style="width: 0%"></div>
</div>
</div>

<div class="part-info">
<h3>üìö Lerneinheit Teil 1</h3>
<p>Dieser erste Teil behandelt die Grundlagen, Biochemie, klinisches Bild und Diagnostik der Aminos√§urest√∂rungen.</p>
</div>

<div class="navigation">
<button class="nav-btn active" onclick="showSection('grundlagen')">1. Grundlagen</button>
<button class="nav-btn" onclick="showSection('biochemie')">2. Biochemie</button>
<button class="nav-btn" onclick="showSection('klinik')">3. Klinisches Bild</button>
<button class="nav-btn" onclick="showSection('diagnostik')">4. Diagnostik</button>
</div>

<!-- Grundlagen -->
<div class="content-section active" id="grundlagen">
<h2 class="section-title">üéØ Grundlagen der Aminos√§urest√∂rungen</h2>

<div class="subsection">
<h3>Definition und √úberblick</h3>
<p>Aminos√§urest√∂rungen sind angeborene Stoffwechseldefekte, die den Abbau oder Transport von Aminos√§uren betreffen. Sie geh√∂ren zu den h√§ufigsten Stoffwechselerkrankungen und k√∂nnen unbehandelt zu schweren neurologischen Sch√§den f√ºhren.</p>

<div class="highlight-box">
<h4>Wichtige Aminos√§urest√∂rungen</h4>
<ul>
<li><strong>PKU</strong> - Phenylketonurie (h√§ufigste Form)</li>
<li><strong>MSUD</strong> - Ahornsirupkrankheit (Maple Syrup Urine Disease)</li>
<li><strong>Homocystinurie</strong> - St√∂rung des Methioninstoffwechsels</li>
<li><strong>Tyrosin√§mie</strong> - Defekte im Tyrosinabbau</li>
<li><strong>Alkaptonie</strong> - St√∂rung des Phenylalanin-/Tyrosinabbaus</li>
<li><strong>Harnstoffzyklusdefekte</strong> - Hyperammon√§mie-Syndrome</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Epidemiologie</h3>
<table class="clinical-table">
<thead>
<tr>
<th>Erkrankung</th>
<th>Inzidenz</th>
<th>Vererbung</th>
<th>Hauptgen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PKU</strong></td>
<td>1:10.000</td>
<td>autosomal-rezessiv</td>
<td>PAH</td>
</tr>
<tr>
<td><strong>MSUD</strong></td>
<td>1:185.000</td>
<td>autosomal-rezessiv</td>
<td>BCKDHA, BCKDHB, DBT</td>
</tr>
<tr>
<td><strong>Homocystinurie</strong></td>
<td>1:200.000</td>
<td>autosomal-rezessiv</td>
<td>CBS</td>
</tr>
<tr>
<td><strong>Tyrosin√§mie I</strong></td>
<td>1:100.000</td>
<td>autosomal-rezessiv</td>
<td>FAH</td>
</tr>
<tr>
<td><strong>OTC-Mangel</strong></td>
<td>1:50.000</td>
<td>X-chromosomal</td>
<td>OTC</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Pathophysiologie - √úberblick</h3>
<div class="pathway-diagram">
<h4>Drei Hauptmechanismen der Krankheitsentstehung</h4>
<div style="display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 20px; margin: 20px 0;">
<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
<h5 style="color: #dc2626; margin-bottom: 15px;">‚ò¢Ô∏è Substratakkumulation</h5>
<p style="color: #dc2626;">Anstau toxischer Substrate</p>
<div class="arrow" style="color: #dc2626;">‚Üì</div>
<p style="color: #dc2626;">Organsch√§digung</p>
</div>
<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fff7ed, #fed7aa); border-radius: 12px; border: 2px solid #f97316;">
<h5 style="color: #ea580c; margin-bottom: 15px;">‚ö° Produktdefizit</h5>
<p style="color: #ea580c;">Mangel an wichtigen Produkten</p>
<div class="arrow" style="color: #ea580c;">‚Üì</div>
<p style="color: #ea580c;">Funktionsst√∂rungen</p>
</div>
<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #f0f9ff, #e0f2fe); border-radius: 12px; border: 2px solid #0ea5e9;">
<h5 style="color: #0284c7; margin-bottom: 15px;">üîÑ Alternative Wege</h5>
<p style="color: #0284c7;">Bildung abnormaler Metabolite</p>
<div class="arrow" style="color: #0284c7;">‚Üì</div>
<p style="color: #0284c7;">Sekund√§re Effekte</p>
</div>
</div>
</div>
</div>

<div class="subsection">
<h3>Klassifikation nach Stoffwechselweg</h3>
<div class="pathway-diagram">
<h4>Hauptkategorien</h4>
<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 20px 0;">
<div style="text-align: center;">
<div class="enzyme-box">Aromatische AS</div>
<p style="margin: 10px 0;">PKU, Tyrosin√§mie, Alkaptonie</p>
<div class="metabolite-box" style="margin: 5px auto;">Phe ‚Üí Tyr Pathway</div>
</div>
<div style="text-align: center;">
<div class="enzyme-box">Verzweigtkettige AS</div>
<p style="margin: 10px 0;">MSUD, Isovaleriazid√§mie</p>
<div class="metabolite-box" style="margin: 5px auto;">Leucin, Isoleucin, Valin</div>
</div>
<div style="text-align: center;">
<div class="enzyme-box">Schwefelhaltige AS</div>
<p style="margin: 10px 0;">Homocystinurie, Cystinurie</p>
<div class="metabolite-box" style="margin: 5px auto;">Methionin, Cystein</div>
</div>
<div style="text-align: center;">
<div class="enzyme-box">Harnstoffzyklus</div>
<p style="margin: 10px 0;">OTC, ASS, ASL-Mangel</p>
<div class="metabolite-box" style="margin: 5px auto;">NH‚ÇÉ-Entgiftung</div>
</div>
</div>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('biochemie')">Weiter zur Biochemie ‚Üí</button>
</div>
</div>

<!-- Biochemie -->
<div class="content-section" id="biochemie">
<h2 class="section-title">‚öóÔ∏è Biochemische Grundlagen</h2>

<div class="subsection">
<h3>1. Aminos√§uren: Struktur und Klassifikation</h3>
<div class="highlight-box">
<h4>Grundstruktur</h4>
<p><strong>Allgemeine Formel:</strong> H‚ÇÇN-CHR-COOH</p>
<div style="font-family: monospace; font-size: 1.1em; margin: 10px 0; text-align: center;">
<span style="color: #2563eb;">H‚ÇÇN</span>-
<span style="color: #16a34a;">CH</span>-
<span style="color: #dc2626;">COOH</span><br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="color: #ea580c;">|</span><br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="color: #ea580c;">R</span>
</div>
<div style="font-size: 0.9em; text-align: center;">
<span style="color: #2563eb;">‚ñ† Aminogruppe</span> |
<span style="color: #16a34a;">‚ñ† Œ±-C-Atom</span> |
<span style="color: #dc2626;">‚ñ† Carboxylgruppe</span> |
<span style="color: #ea580c;">‚ñ† Seitenkette (R)</span>
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Kategorie</th>
<th>Eigenschaften</th>
<th>Beispiele</th>
<th>Klinische Bedeutung</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aromatische AS</strong></td>
<td>Benzolring in Seitenkette</td>
<td>Phenylalanin, Tyrosin, Tryptophan</td>
<td>PKU, Tyrosin√§mie</td>
</tr>
<tr>
<td><strong>Verzweigtkettige AS</strong></td>
<td>Verzweigte aliphatische Kette</td>
<td>Leucin, Isoleucin, Valin</td>
<td>MSUD</td>
</tr>
<tr>
<td><strong>Schwefelhaltige AS</strong></td>
<td>Schwefel in Seitenkette</td>
<td>Methionin, Cystein</td>
<td>Homocystinurie</td>
</tr>
<tr>
<td><strong>Basische AS</strong></td>
<td>Positive Ladung bei pH 7</td>
<td>Lysin, Arginin, Histidin</td>
<td>Lysinurie, Harnstoffzyklus</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>2. Phenylalanin-Tyrosin-Stoffwechsel</h3>
<div class="pathway-diagram">
<h4>Der Phenylalanin-Abbauweg</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Phenylalanin</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">PAH (BH‚ÇÑ)</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Tyrosin</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: Hydroxylierung (PAH = Phenylalanin-Hydroxylase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Tyrosin</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">TAT</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">4-OH-Phenylpyruvat</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 2: Transaminierung (TAT = Tyrosin-Aminotransferase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">4-OH-Phenylpyruvat</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">HPD</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Homogentisinat</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 3: Hydroxylierung (HPD = 4-OH-Phenylpyruvat-Dioxygenase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Homogentisinat</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">HGD</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Maleylacetoacetat</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 4: Ringspaltung (HGD = Homogentisinat-Dioxygenase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Maleylacetoacetat</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">FAH</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Fumarat + Acetoacetat</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 5: Hydrolysierung (FAH = Fumarylacetoacetat-Hydrolase)</div>
</div>

<p style="text-align: center; font-weight: bold; margin-top: 1rem;"><strong>Endprodukte:</strong> Fumarat (‚Üí Glukoneogenese) + Acetoacetat (‚Üí Ketonk√∂rper)</p>
</div>

<div class="highlight-box">
<h4>Krankheiten des Phenylalanin-Tyrosin-Weges</h4>
<ul>
<li><strong>PKU (PAH-Mangel):</strong> Phenylalanin ‚Üë‚Üë, Tyrosin ‚Üì</li>
<li><strong>Tyrosin√§mie II (TAT-Mangel):</strong> Tyrosin ‚Üë‚Üë, Cornea-/Hautl√§sionen</li>
<li><strong>Tyrosin√§mie III (HPD-Mangel):</strong> 4-OH-Phenylpyruvat ‚Üë, meist mild</li>
<li><strong>Alkaptonie (HGD-Mangel):</strong> Homogentisinat ‚Üë, Ochronose</li>
<li><strong>Tyrosin√§mie I (FAH-Mangel):</strong> Succinylaceton ‚Üë, Leberzirrhose</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>3. Verzweigtkettige Aminos√§uren (BCAA)</h3>
<div class="pathway-diagram">
<h4>Gemeinsamer Abbauweg von Leucin, Isoleucin, Valin</h4>
<div style="background: linear-gradient(90deg, #f3f4f6 50%, #e5e7eb 50%); padding: 20px; border-radius: 10px; margin: 20px 0;">
<div style="text-align: center; margin-bottom: 15px;">
<span style="margin-right: 50px; font-weight: bold;">Muskel</span>
<span style="font-weight: bold;">Leber/andere Gewebe</span>
</div>
<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Leucin/Isoleucin/Valin</div>
<span class="arrow" style="margin: 0 10px;">BCAT‚Üí</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">Œ±-Ketos√§uren</div>
</div>
<div style="text-align: center; margin: 15px 0; font-size: 1.2em;">
‚¨áÔ∏è <strong>Transport zur Leber</strong> ‚¨áÔ∏è
</div>
<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">Œ±-Ketos√§uren</div>
<span class="arrow" style="margin: 0 10px;">BCKDH‚Üí</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Acyl-CoA-Derivate</div>
</div>
<div style="text-align: center; margin-top: 15px;">
<span class="arrow">‚Üì</span><br>
<div class="enzyme-box" style="background: linear-gradient(135deg, #2563eb, #1d4ed8);">Weitere Oxidation</div>
</div>
</div>
</div>

<div class="case-study">
<h4>üß¨ MSUD: Ahornsirupkrankheit</h4>
<p><strong>Enzymdefekt:</strong> Branched-Chain Œ±-Ketoacid Dehydrogenase (BCKDH)</p>
<p><strong>Biochemie:</strong></p>
<ul>
<li>Akkumulation von Leucin, Isoleucin, Valin</li>
<li>Erh√∂hte Œ±-Ketos√§uren (Œ±-Ketoisocaproat, Œ±-Keto-Œ≤-methylvalerat, Œ±-Ketoisovalerat)</li>
<li>Bildung von Alloisoleucin (pathognomonisch)</li>
<li>S√º√ülicher Geruch (Sotolone aus Leucin-Metaboliten)</li>
</ul>
<p><strong>Pathophysiologie:</strong></p>
<ul>
<li>Leucin toxisch f√ºr das ZNS (Aminos√§ure-Transporter-Blockade)</li>
<li>Gest√∂rte Protein-/Neurotransmitter-Synthese</li>
<li>Zerebrale √ñdeme bei akuter Dekompensation</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>4. Harnstoffzyklus</h3>
<div class="pathway-diagram">
<h4>Ammoniakentgiftung √ºber den Harnstoffzyklus</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 20px; background: linear-gradient(135deg, #f0f9ff, #e0f2fe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #0ea5e9;">
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">NH‚ÇÉ</div>
<span style="margin: 0 5px;">+</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d);">CO‚ÇÇ</div>
<span class="arrow">CPS1‚Üí</span>
<div class="enzyme-box">Carbamoylphosphat</div>
</div>
<div style="text-align: center; font-size: 0.9em; color: #0284c7;">Schritt 1: CPS1 (Carbamoylphosphat-Synthetase I)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Carbamoylphosphat</div>
<span style="margin: 0 5px;">+</span>
<div class="enzyme-box">Ornithin</div>
<span class="arrow">OTC‚Üí</span>
<div class="enzyme-box">Citrullin</div>
</div>
<div style="text-align: center; font-size: 0.9em; color: #0284c7;">Schritt 2: OTC (Ornithin-Transcarbamylase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Citrullin</div>
<span style="margin: 0 5px;">+</span>
<div class="enzyme-box">Aspartat</div>
<span class="arrow">ASS‚Üí</span>
<div class="enzyme-box">Argininosuccinat</div>
</div>
<div style="text-align: center; font-size: 0.9em; color: #0284c7;">Schritt 3: ASS (Argininosuccinat-Synthetase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Argininosuccinat</div>
<span class="arrow">ASL‚Üí</span>
<div class="enzyme-box">Arginin</div>
<span style="margin: 0 5px;">+</span>
<div class="enzyme-box">Fumarat</div>
</div>
<div style="text-align: center; font-size: 0.9em; color: #0284c7;">Schritt 4: ASL (Argininosuccinat-Lyase)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Arginin</div>
<span class="arrow">ARG‚Üí</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #22c55e, #16a34a);">Harnstoff</div>
<span style="margin: 0 5px;">+</span>
<div class="enzyme-box">Ornithin</div>
</div>
<div style="text-align: center; font-size: 0.9em; color: #0284c7;">Schritt 5: ARG (Arginase)</div>
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Enzymdefekt</th>
<th>Akkumulierendes Substrat</th>
<th>Diagnostischer Marker</th>
<th>Schweregrad</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPS1-Mangel</strong></td>
<td>NH‚ÇÉ</td>
<td>Citrullin ‚Üì, Orotinat normal</td>
<td>Schwer</td>
</tr>
<tr>
<td><strong>OTC-Mangel</strong></td>
<td>NH‚ÇÉ, Carbamoylphosphat</td>
<td>Citrullin ‚Üì, Orotinat ‚Üë‚Üë</td>
<td>Sehr schwer</td>
</tr>
<tr>
<td><strong>ASS-Mangel</strong></td>
<td>Citrullin</td>
<td>Citrullin ‚Üë‚Üë‚Üë (>1000 Œºmol/l)</td>
<td>Mittel-schwer</td>
</tr>
<tr>
<td><strong>ASL-Mangel</strong></td>
<td>Argininosuccinat</td>
<td>Argininosuccinat ‚Üë‚Üë</td>
<td>Mittel</td>
</tr>
<tr>
<td><strong>ARG-Mangel</strong></td>
<td>Arginin</td>
<td>Arginin ‚Üë‚Üë</td>
<td>Mild</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>5. Schwefelhaltige Aminos√§uren</h3>
<div class="pathway-diagram">
<h4>Methionin-Homocystein-Zyklus</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Methionin</div>
<span class="arrow">MAT‚Üí</span>
<div class="enzyme-box">S-Adenosylmethionin</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">S-Adenosylhomocystein</div>
</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">S-Adenosylhomocystein</div>
<span class="arrow">SAHH‚Üí</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Homocystein</div>
</div>

<div style="text-align: center; margin: 20px 0;">
<p style="font-weight: bold;">Homocystein kann zwei Wege einschlagen:</p>
</div>

<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px;">
<div style="text-align: center;">
<h5 style="color: #16a34a;">Remethylierung</h5>
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626); margin: 10px auto;">Homocystein</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div style="font-size: 0.9em; margin: 5px;">MS (B‚ÇÅ‚ÇÇ) oder BHMT</div>
<div class="enzyme-box" style="margin: 10px auto;">Methionin</div>
</div>
<div style="text-align: center;">
<h5 style="color: #dc2626;">Transsulfurierung</h5>
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626); margin: 10px auto;">Homocystein</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div style="font-size: 0.9em; margin: 5px;">CBS (B‚ÇÜ)</div>
<div class="enzyme-box" style="margin: 10px auto;">Cystathionin ‚Üí Cystein</div>
</div>
</div>
</div>
</div>

<div class="case-study">
<h4>üß¨ Homocystinurie</h4>
<p><strong>H√§ufigste Form:</strong> Cystathionin-Œ≤-Synthase (CBS) Mangel</p>
<p><strong>Biochemie:</strong></p>
<ul>
<li>Homocystein und Methionin stark erh√∂ht</li>
<li>Cystin im Urin (Disulfidbr√ºcken-Bildung)</li>
<li>Reduzierte Cysteinbildung</li>
</ul>
<p><strong>Pathophysiologie:</strong></p>
<ul>
<li>Homocystein st√∂rt Kollagen-Quervernetzung</li>
<li>Endothelsch√§digung ‚Üí Thromboseneigung</li>
<li>Linsenluxation durch schwaches Zonulagewebe</li>
<li>Skelettanomalien (Marfan-√§hnlich)</li>
</ul>
<p><strong>B‚ÇÜ-responsive Formen:</strong> ~50% sprechen auf Pyridoxin an</p>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('klinik')">Weiter zum klinischen Bild ‚Üí</button>
</div>
</div>

<!-- Klinisches Bild -->
<div class="content-section" id="klinik">
<h2 class="section-title">üè• Klinisches Bild</h2>

<div class="subsection">
<h3>PKU - Phenylketonurie</h3>
<div class="case-study">
<h4>üìã Klassische PKU</h4>
<p><strong>Unbehandelt (historischer Verlauf):</strong></p>
<ul>
<li>Normale Entwicklung in den ersten 2-6 Monaten</li>
<li>Entwicklungsr√ºckstand ab 6-12 Monaten</li>
<li>Schwere geistige Behinderung (IQ <50)</li>
<li>Mikrozephalie, Epilepsie (bei 25%)</li>
<li>Verhaltensst√∂rungen, Autismus-Spektrum</li>
</ul>
<p><strong>K√∂rperliche Merkmale:</strong></p>
<ul>
<li>Helle Haut, blonde Haare, blaue Augen</li>
<li>M√§usegeruch des Urins (Phenylacetat)</li>
<li>Ekzeme, Hautausschl√§ge</li>
<li>Normale Geburt und Neugeborenenperiode</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>PKU-Variante</th>
<th>Phe-Spiegel (Œºmol/l)</th>
<th>PAH-Restaktivit√§t</th>
<th>Klinik</th>
<th>Therapie</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Klassische PKU</strong></td>
<td>>1200</td>
<td><2%</td>
<td>Schwere geistige Behinderung</td>
<td>Strenge Phe-arme Di√§t</td>
</tr>
<tr>
<td><strong>Milde PKU</strong></td>
<td>600-1200</td>
<td>2-5%</td>
<td>Milde Entwicklungsst√∂rung</td>
<td>M√§√üige Phe-Restriktion</td>
</tr>
<tr>
<td><strong>Milde HPA</strong></td>
<td>120-600</td>
<td>5-10%</td>
<td>Meist normal</td>
<td>Keine/minimale Di√§t</td>
</tr>
<tr>
<td><strong>BH‚ÇÑ-responsive PKU</strong></td>
<td>Variabel</td>
<td>Erhaltene Aktivit√§t</td>
<td>Abh√§ngig von Behandlung</td>
<td>BH‚ÇÑ-Supplementation</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Maternale PKU</h4>
<p><strong>Problem:</strong> Schwangere PKU-Patientinnen mit schlechter Di√§tf√ºhrung</p>
<p><strong>Folgen f√ºr das Kind:</strong></p>
<ul>
<li>Geistige Behinderung (auch bei normalem Kind!)</li>
<li>Mikrozephalie</li>
<li>Angeborene Herzfehler</li>
<li>Intrauterine Wachstumsretardierung</li>
</ul>
<p><strong>Pr√§vention:</strong> Phe-Werte <360 Œºmol/l vor Konzeption und w√§hrend Schwangerschaft</p>
</div>
</div>

<div class="subsection">
<h3>MSUD - Ahornsirupkrankheit</h3>
<table class="clinical-table">
<thead>
<tr>
<th>MSUD-Typ</th>
<th>Enzymaktivit√§t</th>
<th>Klinik</th>
<th>Prognose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Klassisch</strong></td>
<td><2%</td>
<td>Schwere neonatale Enzephalopathie</td>
<td>Schlecht ohne Behandlung</td>
</tr>
<tr>
<td><strong>Intermedi√§r</strong></td>
<td>3-8%</td>
<td>Entwicklungsverz√∂gerung, episodische Krisen</td>
<td>M√§√üig bei Behandlung</td>
</tr>
<tr>
<td><strong>Intermittierend</strong></td>
<td>8-15%</td>
<td>Normal bis zur ersten Krise</td>
<td>Gut bei Krisenmanagement</td>
</tr>
<tr>
<td><strong>Thiamin-responsiv</strong></td>
<td>Variabel</td>
<td>Wie intermedi√§r</td>
<td>Sehr gut bei B‚ÇÅ-Therapie</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üö® Klassische MSUD - Neonataler Verlauf</h4>
<p><strong>Tag 1-3:</strong> Meist unauff√§llig</p>
<p><strong>Tag 4-7:</strong></p>
<ul>
<li>S√º√ülicher Ahornsirup-Geruch (pathognomonisch)</li>
<li>Trinkschw√§che, Lethargie</li>
<li>Erbrechen, Gedeihst√∂rung</li>
<li>Muskelhypotonie</li>
</ul>
<p><strong>Tag 7-14 (unbehandelt):</strong></p>
<ul>
<li>Zerebrale Krampfanf√§lle</li>
<li>Dezerebrationsstellung</li>
<li>Koma, Ateminsuffizienz</li>
<li>Tod durch Hirn√∂dem</li>
</ul>
<p><strong>Ausl√∂ser f√ºr Krisen (bei milderen Formen):</strong></p>
<ul>
<li>Infekte mit Katabolismus</li>
<li>Erh√∂hte Proteinzufuhr</li>
<li>Operationen, Trauma</li>
<li>Fasten, Dehydratation</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Harnstoffzyklusdefekte</h3>
<div class="pathway-diagram">
<h4>Klinik nach Manifestationsalter</h4>
<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 20px 0;">
<div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
<h5 style="color: #dc2626; margin-bottom: 10px;">üë∂ Neonatal</h5>
<ul style="font-size: 0.9em; color: #dc2626;">
<li>Hyperammon√§mie >500 Œºmol/l</li>
<li>Koma, Krampfanf√§lle</li>
<li>Atemalkaliose initial</li>
<li>Hypothermie, Hypotonie</li>
<li>Hohe Mortalit√§t</li>
</ul>
</div>
<div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
<h5 style="color: #ea580c; margin-bottom: 10px;">üçº Infantil</h5>
<ul style="font-size: 0.9em; color: #ea580c;">
<li>Rezidivierende Erbrechen</li>
<li>Gedeihst√∂rung</li>
<li>Entwicklungsverz√∂gerung</li>
<li>Hepatomegalie</li>
<li>Proteinaversion</li>
</ul>
</div>
<div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
<h5 style="color: #16a34a; margin-bottom: 10px;">üßí Sp√§tmanifest</h5>
<ul style="font-size: 0.9em; color: #16a34a;">
<li>Verhaltensst√∂rungen</li>
<li>Lernschwierigkeiten</li>
<li>Episodische Bewusstseinsst√∂rungen</li>
<li>Migr√§ne-√§hnliche Symptome</li>
<li>Proteinaversion, Erbrechen</li>
</ul>
</div>
</div>
</div>

<div class="highlight-box">
<h4>Hyperammon√§mische Krise</h4>
<p><strong>Laborwerte:</strong></p>
<ul>
<li>Ammoniak >150 Œºmol/l (N: <50)</li>
<li>Bei Werten >300 Œºmol/l: Dialyse indiziert</li>
<li>Bei Werten >500 Œºmol/l: Lebensgefahr</li>
</ul>
<p><strong>Klinische Zeichen:</strong></p>
<ul>
<li>Bewusstseinstr√ºbung bis Koma</li>
<li>Zerebrale Krampfanf√§lle</li>
<li>Neurologische Herdsymptome</li>
<li>Hirndruckzeichen</li>
</ul>
<p><strong>Langzeitfolgen:</strong> Irreversible Hirnsch√§digung proportional zu Schwere und Dauer</p>
</div>
</div>

<div class="subsection">
<h3>Tyrosin√§mie</h3>
<table class="clinical-table">
<thead>
<tr>
<th>Typ</th>
<th>Enzymdefekt</th>
<th>Hauptsymptome</th>
<th>Besonderheiten</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tyrosin√§mie I</strong></td>
<td>FAH (Fumarylacetoacetat-Hydrolase)</td>
<td>Leberzirrhose, Nierensch√§den</td>
<td>Succinylaceton toxisch, HCC-Risiko</td>
</tr>
<tr>
<td><strong>Tyrosin√§mie II</strong></td>
<td>TAT (Tyrosin-Aminotransferase)</td>
<td>Kornea-L√§sionen, Hautl√§sionen</td>
<td>Tyrosin-Kristalle in Geweben</td>
</tr>
<tr>
<td><strong>Tyrosin√§mie III</strong></td>
<td>HPD (4-OH-Phenylpyruvat-Dioxygenase)</td>
<td>Meist asymptomatisch</td>
<td>Benigner Verlauf</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üî¨ Tyrosin√§mie I - Verlaufsformen</h4>
<p><strong>Akute Form (0-2 Jahre):</strong></p>
<ul>
<li>Akutes Leberversagen</li>
<li>Gerinnungsst√∂rungen</li>
<li>Hypoglyk√§mie</li>
<li>Fanconi-Syndrom (proximale Tubulopathie)</li>
<li>Hohes Letalit√§tsrisiko</li>
</ul>
<p><strong>Chronische Form (>2 Jahre):</strong></p>
<ul>
<li>Progressive Leberzirrhose</li>
<li>Hepatozellul√§res Karzinom (90% bis 10. LJ!)</li>
<li>Chronische Niereninsuffizienz</li>
<li>Porphyrie-√§hnliche Krisen (Neuropathie)</li>
<li>Rachitis (renaler Phosphatverlust)</li>
</ul>
<p><strong>NTBC-Therapie revolution√§r:</strong> Blockiert Succinylaceton-Bildung ‚Üí dramatische Verbesserung</p>
</div>
</div>

<div class="subsection">
<h3>Homocystinurie</h3>
<div class="pathway-diagram">
<h4>Multisystemerkrankung</h4>
<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 20px; margin: 20px 0;">
<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">ZNS</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>Geistige Behinderung</li>
<li>Epilepsie</li>
<li>Thromboembolien</li>
<li>Schlaganfall</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Augen</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>Linsenluxation (90%)</li>
<li>Myopie</li>
<li>Glaukom</li>
<li>Retinadegeneration</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #f97316, #ea580c);">Skelett</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>Marfanoider Habitus</li>
<li>Arachnodaktylie</li>
<li>Pectus-Deformit√§t</li>
<li>Osteoporose</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d);">Kardiovaskul√§r</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>Thrombosen (arteriell/ven√∂s)</li>
<li>Fr√ºhzeitige Koronarsklerose</li>
<li>Pulmonale Embolie</li>
<li>Endothelsch√§den</li>
</ul>
</div>
</div>
</div>

<div class="highlight-box">
<h4>B‚ÇÜ-responsive vs. B‚ÇÜ-non-responsive Homocystinurie</h4>
<p><strong>B‚ÇÜ-responsive (50% der F√§lle):</strong></p>
<ul>
<li>Restaktivit√§t der CBS vorhanden</li>
<li>Milder Ph√§notyp, sp√§ter Beginn</li>
<li>Gutes Ansprechen auf Pyridoxin (B‚ÇÜ)</li>
<li>Normale Intelligenz bei fr√ºher Therapie</li>
</ul>
<p><strong>B‚ÇÜ-non-responsive:</strong></p>
<ul>
<li>Kompletter CBS-Mangel</li>
<li>Schwerer Ph√§notyp, fr√ºher Beginn</li>
<li>Betain + Fols√§ure + B‚ÇÅ‚ÇÇ n√∂tig</li>
<li>Methionin-arme Di√§t erforderlich</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('diagnostik')">Weiter zur Diagnostik ‚Üí</button>
</div>
</div>

<!-- Diagnostik -->
<div class="content-section" id="diagnostik">
<h2 class="section-title">üî¨ Diagnostik</h2>

<div class="subsection">
<h3>Neugeborenenscreening</h3>
<div class="case-study">
<h4>ü©∏ Guthrie-Test: Erfolgsstory der Pr√§vention</h4>
<p><strong>Screened in Deutschland seit:</strong></p>
<ul>
<li>PKU: 1971 (erste Krankheit √ºberhaupt)</li>
<li>MSUD: 2005 (erweiterte Screening)</li>
<li>Homocystinurie: 2019</li>
<li>Tyrosin√§mie I: 2019</li>
</ul>
<p><strong>Methodik:</strong></p>
<ul>
<li>Trockenblut auf Filterkarton (36-72h nach Geburt)</li>
<li>Tandem-Massenspektrometrie (MS/MS)</li>
<li>Automatisierte Auswertung mit Cut-off-Werten</li>
<li>Kontrolle durch zweites Screening m√∂glich</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Erkrankung</th>
<th>Marker</th>
<th>Cut-off</th>
<th>Sensitivit√§t</th>
<th>Spezifit√§t</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PKU</strong></td>
<td>Phenylalanin</td>
<td>>120 Œºmol/l</td>
<td>>99%</td>
<td>99,8%</td>
</tr>
<tr>
<td><strong>MSUD</strong></td>
<td>Leucin</td>
<td>>200 Œºmol/l</td>
<td>~95%</td>
<td>99,9%</td>
</tr>
<tr>
<td><strong>Tyrosin√§mie I</strong></td>
<td>Tyrosin + Succinylaceton</td>
<td>Variabel</td>
<td>~90%</td>
<td>99,5%</td>
</tr>
<tr>
<td><strong>Homocystinurie</strong></td>
<td>Methionin</td>
<td>>40 Œºmol/l</td>
<td>~85%</td>
<td>99,7%</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Grenzen des Neugeborenenscreenings</h4>
<p><strong>Falsch-negative Ergebnisse m√∂glich bei:</strong></p>
<ul>
<li>Zu fr√ºher Blutentnahme (<24h)</li>
<li>Milden Varianten mit geringer Stoffwechselst√∂rung</li>
<li>Maternaler PKU (Kind kann trotz normalem Screening betroffen sein)</li>
<li>BH‚ÇÑ-Mangelformen der PKU</li>
</ul>
<p><strong>Falsch-positive Ergebnisse bei:</strong></p>
<ul>
<li>Fr√ºhgeburtlichkeit</li>
<li>Parenteraler Ern√§hrung</li>
<li>Antibiotika-Therapie</li>
<li>Lebererkrankungen anderer Ursache</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Aminos√§ure-Analytik</h3>
<div class="pathway-diagram">
<h4>Methodisches Vorgehen</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Plasma-AS</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">S√§ulenchromatographie</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Ninhydrin-Detektion</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Standardmethode: Ionenaustausch-Chromatographie</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Trockenblut</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">MS/MS</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Direktanalyse</div>
</div>
<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Screening-Methode: Tandem-Massenspektrometrie</div>
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Aminos√§ure</th>
<th>Normbereich (Œºmol/l)</th>
<th>Pathologisch erh√∂ht bei</th>
<th>Klinische Relevanz</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenylalanin</strong></td>
<td>30-80</td>
<td>PKU, BH‚ÇÑ-Mangel</td>
<td>Neurotoxisch ab >400</td>
</tr>
<tr>
<td><strong>Tyrosin</strong></td>
<td>40-120</td>
<td>Tyrosin√§mie I-III</td>
<td>Leber-/Nierensch√§den</td>
</tr>
<tr>
<td><strong>Leucin</strong></td>
<td>80-200</td>
<td>MSUD</td>
<td>ZNS-toxisch ab >400</td>
</tr>
<tr>
<td><strong>Methionin</strong></td>
<td>10-50</td>
<td>Homocystinurie, Lebererkrankung</td>
<td>Thromboserisiko</td>
</tr>
<tr>
<td><strong>Citrullin</strong></td>
<td>10-45</td>
<td>ASS-Mangel</td>
<td>Marker f√ºr Harnstoffzyklus</td>
</tr>
<tr>
<td><strong>Arginin</strong></td>
<td>40-120</td>
<td>Arginase-Mangel</td>
<td>Spastik, Krampfanf√§lle</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Spezialdiagnostik</h3>
<div class="case-study">
<h4>üî¨ PKU: Differentialdiagnose der Hyperphenylalanin√§mie</h4>
<p><strong>1. Klassische PKU vs. BH‚ÇÑ-Mangel:</strong></p>
<ul>
<li>BH‚ÇÑ-Belastungstest (20 mg/kg p.o.)</li>
<li>Bei BH‚ÇÑ-Mangel: Phe-Abfall >30% nach 8h</li>
<li>Zus√§tzlich: Pterin-Analyse im Urin</li>
<li>DHPR-Aktivit√§t in Trockenblut</li>
</ul>
<p><strong>2. Phenylalanin-Toleranztest:</strong></p>
<ul>
<li>100 mg/kg Phenylalanin p.o.</li>
<li>Phe-Anstieg bei PKU >20-fach</li>
<li>Bei Gesunden: nur 2-3-fach</li>
</ul>
</div>

<div class="highlight-box">
<h4>BH‚ÇÑ-Mangelformen</h4>
<p><strong>Ursachen des Biopterin-Mangels:</strong></p>
<ul>
<li><strong>GTP-Cyclohydrolase-I-Mangel:</strong> Biosynthese-Defekt</li>
<li><strong>6-Pyruvoyl-Tetrahydropterin-Synthase-Mangel:</strong> H√§ufigste Form</li>
<li><strong>Dihydropteridin-Reduktase-Mangel:</strong> Recycling-Defekt</li>
<li><strong>Primakinin-4a-Carbinolamin-Dehydratase-Mangel:</strong> Sehr selten</li>
</ul>
<p><strong>Besonderheit:</strong> Betrifft auch Tyrosin-Hydroxylase und Tryptophan-Hydroxylase</p>
<p><strong>Zusatzsymptome:</strong> Dopamin-/Serotonin-Mangel ‚Üí Bewegungsst√∂rungen, Krampfanf√§lle</p>
</div>
</div>

<div class="subsection">
<h3>Organische S√§uren im Urin</h3>
<table class="clinical-table">
<thead>
<tr>
<th>Erkrankung</th>
<th>Charakteristische Organische S√§uren</th>
<th>Pathophysiologie</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PKU</strong></td>
<td>Phenylbrenztraubens√§ure, Phenylmilchs√§ure, Phenylacetat</td>
<td>Alternative Abbauwege von Phenylalanin</td>
</tr>
<tr>
<td><strong>MSUD</strong></td>
<td>Œ±-Ketoisocaproat, Œ±-Keto-Œ≤-methylvalerat, Œ±-Ketoisovalerat</td>
<td>Akkumulation der Œ±-Ketos√§uren</td>
</tr>
<tr>
<td><strong>Tyrosin√§mie I</strong></td>
<td>Succinylaceton (pathognomonisch)</td>
<td>Toxisches Nebenprodukt von Fumaryacetoacetat</td>
</tr>
<tr>
<td><strong>Homocystinurie</strong></td>
<td>Homocystin, homocystisch-gemischte Disulfide</td>
<td>Oxidation von Homocystein zu Disulfiden</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üß™ MSUD: Alloisoleucin als Biomarker</h4>
<p><strong>Entstehung:</strong></p>
<ul>
<li>Nicht-enzymatische Racemisierung von Œ±-Keto-Œ≤-methylvalerat</li>
<li>Reaminierung zu Alloisoleucin</li>
<li>Kommt nur bei MSUD vor (pathognomonisch!)</li>
</ul>
<p><strong>Diagnostischer Wert:</strong></p>
<ul>
<li>Spezifisch f√ºr MSUD (100% Spezifit√§t)</li>
<li>Erh√∂ht auch bei milden Formen</li>
<li>Monitoring des Therapieerfolgs</li>
<li>Fr√ºherkennung von Dekompensationen</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Molekulargenetik</h3>
<div class="pathway-diagram">
<h4>Genetische Diagnostik</h4>
<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 20px 0;">
<div style="text-align: center;">
<div class="enzyme-box">PKU (PAH-Gen)</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>>500 bekannte Mutationen</li>
<li>R408W h√§ufigste in Europa (25%)</li>
<li>IVS10-11G>A in T√ºrkei h√§ufig</li>
<li>Genotyp-Ph√§notyp-Korrelation</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box">MSUD (3 Gene)</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>BCKDHA (E1Œ±, Chromosom 19)</li>
<li>BCKDHB (E1Œ≤, Chromosom 6)</li>
<li>DBT (E2, Chromosom 1)</li>
<li>Founder-Effekt bei Mennoniten</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box">Homocystinurie</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>CBS-Gen (Chromosom 21)</li>
<li>I278T h√§ufigste Mutation</li>
<li>B‚ÇÜ-Responsivit√§t vorhersagbar</li>
<li>833T>C in Irland h√§ufig</li>
</ul>
</div>
<div style="text-align: center;">
<div class="enzyme-box">Harnstoffzyklus</div>
<ul style="font-size: 0.9em; margin: 10px 0; text-align: left;">
<li>OTC: X-chromosomal (Xp21.1)</li>
<li>Carrier-Diagnostik wichtig</li>
<li>Gro√üe Deletionen h√§ufig</li>
<li>Weibliche Symptomatik m√∂glich</li>
</ul>
</div>
</div>
</div>

<div class="highlight-box">
<h4>Pr√§natale Diagnostik</h4>
<p><strong>Indikationen:</strong></p>
<ul>
<li>Bekannte famili√§re Mutation</li>
<li>Vorheriges betroffenes Kind</li>
<li>Carrierstatus beider Eltern</li>
</ul>
<p><strong>Methoden:</strong></p>
<ul>
<li><strong>Chorionzottenbiopsie:</strong> 10.-12. SSW</li>
<li><strong>Amniozentese:</strong> 15.-18. SSW</li>
<li><strong>Pr√§implantationsdiagnostik:</strong> Bei IVF m√∂glich</li>
</ul>
<p><strong>Besonderheit OTC (X-chromosomal):</strong></p>
<ul>
<li>50% Risiko f√ºr S√∂hne von Tr√§gerinnen</li>
<li>Weibliche Tr√§ger k√∂nnen symptomatisch sein</li>
<li>X-Inaktivierungsmuster entscheidend</li>
</ul>
</div>
</div>

<div class="next-step">
<div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
<h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Teil 1 abgeschlossen!</h3>
<p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben die Grundlagen und Diagnostik erfolgreich durchgearbeitet.</p>
<p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Als n√§chstes:</strong> Teil 2 mit Therapie, Prognose, Fallbeispielen und Quiz</p>
<button class="next-btn">Weiter zu Teil 2 ‚Üí</button>
</div>
</div>
</div>
</div>

<script>
let currentSection = 0;
const sections = ['grundlagen', 'biochemie', 'klinik', 'diagnostik'];

function showSection(sectionId) {
// Hide all sections
const allSections = document.querySelectorAll('.content-section');
allSections.forEach(section => section.classList.remove('active'));

// Remove active class from all nav buttons
const allButtons = document.querySelectorAll('.nav-btn');
allButtons.forEach(btn => btn.classList.remove('active'));

// Show selected section
document.getElementById(sectionId).classList.add('active');

// Highlight active nav button
event.target.classList.add('active');

// Update progress bar
currentSection = sections.indexOf(sectionId);
const progress = ((currentSection + 1) / sections.length) * 100;
document.getElementById('progressBar').style.width = progress + '%';

// Scroll to top
window.scrollTo(0, 0);
}

// Initialize progress bar
document.getElementById('progressBar').style.width = '25%';
</script>
</body>
</html>
